Skip to main content
Figure 3 | Trials

Figure 3

From: Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

Figure 3

Proportions of early, additional, and non-responders in group administered C.E.R.A. once every 3 weeks. Intent-to-treat population. 'Early responders': patients with a ≥ 1 g/dL increase in hemoglobin (Hb) from baseline during the first 22 days, with no concomitant blood transfusion during the study.

'Additional responders': patients who were not early responders but achieved the target therapeutic range of 11–13 g/dL during the study without blood transfusion.

'Non-responders': patients who did not qualify as early responders or additional responders.

C.E.R.A.: Continuous Erythropoietin Receptor Activator.

Q3W: once every three weeks.

Back to article page

Trials

ISSN: 1745-6215